H.C. Wainwright raised the firm’s price target on Vericel to $53 from $46 and keeps a Buy rating on the shares post the Q4 report. The analyst says the company’s new MACI product will drive near-term growth.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VCEL:
- Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance
- Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024
- Is VCEL a Buy, Before Earnings?
- Vericel price target raised to $53 from $49 at BTIG
- Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024
